11,Lepor H. The emerging role of alpha antagonists in the therapy ofbenign prostatic hyperplasia. J Urol， 1991，12:389～394
22,Aso Y, Homma Y. Clinical research criteria:response criteria for evaluating efficacy oftreatments of benign prostatic hypertrophy. Br J Urol,1995,76(Suppl 1):69～73
33,Hillman A L, Schwartz J S,Willian M K,et al. The cost-effectiveness of trazosin andplacebo in the traetment of moderate to severe benign prostatic hyperplasia.Urology,1996,47:169～178
44,Roeheborn C G, Oesterling J E, Auerbach S, et al. The hytrin communiyt assessment trialstudy:a one-year study of terazosin versus communiyt assessment trial study:a one-yearstudy of terazosin versus placebo in the treatment of men with symptomatic benignprostatic hyperplasia. Urology,1996,47:159～168
(收稿 2000-04-03)
